SI-BONE, Inc. reported robust financial results for the first quarter ended March 31, 2025, on May 5, 2025. Worldwide revenue reached $47.3 million, representing a 24.9% increase from the corresponding period in 2024, driven by strong underlying procedure demand and new product rollouts.
The company achieved positive adjusted EBITDA of $0.5 million in Q1 2025, a significant improvement from a $4.0 million loss in the prior year period. Gross margin expanded to 79.7%, up from 78.9% in Q1 2024, reflecting improved operational efficiencies.
SI-BONE updated its 2025 worldwide revenue guidance to a range of $193.5 million to $197.5 million, an increase from the prior guidance, implying year-over-year growth of 16% to 18%. The company reiterated its expectation to deliver positive adjusted EBITDA for the full year 2025, underscoring its resilient platform and focus on profitable growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.